Thomas B Richards1, S Jane Henley1, Mary C Puckett1, Hannah K Weir1, Bin Huang2, Thomas C Tucker3, Claudia Allemani4. 1. Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia. 2. Department of Biostatistics, College of Public Health, University of Kentucky, Lexington, Kentucky. 3. Markey Cancer Center, Kentucky Cancer Registry, and College of Public Health, University of Kentucky, Lexington, Kentucky. 4. Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Abstract
BACKGROUND: Results from the second CONCORD study (CONCORD-2) indicated that 5-year net survival for lung cancer was low (range, 10%-20%) between 1995 and 2009 in most countries, including the United States, which was at the higher end of this range. METHODS: Data from CONCORD-2 were used to analyze net survival among patients with lung cancer (aged 15-99 years) who were diagnosed in 37 states covering 80% of the US population. Survival was corrected for background mortality using state-specific and race-specific life tables and age-standardized using International Cancer Survival Standard weights. Net survival was estimated for patients diagnosed between 2001 and 2003 and between 2004 and 2009 at 1, 3, and 5 years after diagnosis by race (all races, black, and white); Surveillance, Epidemiology, and End Results Summary Stage 2000; and US state. RESULTS: Five-year net survival increased from 16.4% (95% confidence interval, 16.3%-16.5%) for patients diagnosed 2001-2003 to 19.0% (18.8%-19.1%) for those diagnosed 2004-2009, with increases in most states and among both blacks and whites. Between 2004 and 2009, 5-year survival was lower among blacks (14.9%) than among whites (19.4%) and ranged by state from 14.5% to 25.2%. CONCLUSIONS: Lung cancer survival improved slightly between the periods 2001-2003 and 2004-2009 but was still low, with variation between states, and persistently lower survival among blacks than whites. Efforts to control well established risk factors would be expected to have the greatest impact on reducing the burden of lung cancer, and efforts to ensure that all patients receive timely and appropriate treatment should reduce the differences in survival by race and state. Cancer 2017;123:5079-99. Published 2017. This article is a U.S. Government work and is in the public domain in the USA. Published 2017. This article is a U.S. Government work and is in the public domain in the USA.
BACKGROUND: Results from the second CONCORD study (CONCORD-2) indicated that 5-year net survival for lung cancer was low (range, 10%-20%) between 1995 and 2009 in most countries, including the United States, which was at the higher end of this range. METHODS: Data from CONCORD-2 were used to analyze net survival among patients with lung cancer (aged 15-99 years) who were diagnosed in 37 states covering 80% of the US population. Survival was corrected for background mortality using state-specific and race-specific life tables and age-standardized using International Cancer Survival Standard weights. Net survival was estimated for patients diagnosed between 2001 and 2003 and between 2004 and 2009 at 1, 3, and 5 years after diagnosis by race (all races, black, and white); Surveillance, Epidemiology, and End Results Summary Stage 2000; and US state. RESULTS: Five-year net survival increased from 16.4% (95% confidence interval, 16.3%-16.5%) for patients diagnosed 2001-2003 to 19.0% (18.8%-19.1%) for those diagnosed 2004-2009, with increases in most states and among both blacks and whites. Between 2004 and 2009, 5-year survival was lower among blacks (14.9%) than among whites (19.4%) and ranged by state from 14.5% to 25.2%. CONCLUSIONS:Lung cancer survival improved slightly between the periods 2001-2003 and 2004-2009 but was still low, with variation between states, and persistently lower survival among blacks than whites. Efforts to control well established risk factors would be expected to have the greatest impact on reducing the burden of lung cancer, and efforts to ensure that all patients receive timely and appropriate treatment should reduce the differences in survival by race and state. Cancer 2017;123:5079-99. Published 2017. This article is a U.S. Government work and is in the public domain in the USA. Published 2017. This article is a U.S. Government work and is in the public domain in the USA.
Authors: William D Travis; Elisabeth Brambilla; Allen P Burke; Alexander Marx; Andrew G Nicholson Journal: J Thorac Oncol Date: 2015-09 Impact factor: 15.609
Authors: Claudia Allemani; Rhea Harewood; Christopher J Johnson; Helena Carreira; Devon Spika; Audrey Bonaventure; Kevin Ward; Hannah K Weir; Michel P Coleman Journal: Cancer Date: 2017-12-15 Impact factor: 6.860
Authors: Jacqueline W Miller; Judith Lee Smith; A Blythe Ryerson; Thomas C Tucker; Claudia Allemani Journal: Cancer Date: 2017-12-15 Impact factor: 6.860
Authors: Sherri L Stewart; Rhea Harewood; Melissa Matz; Sun Hee Rim; Susan A Sabatino; Kevin C Ward; Hannah K Weir Journal: Cancer Date: 2017-12-15 Impact factor: 6.860
Authors: Adil H Haider; Irene Dankwa-Mullan; Allysha C Maragh-Bass; Maya Torain; Cheryl K Zogg; Elizabeth J Lilley; Lisa M Kodadek; Navin R Changoor; Peter Najjar; John A Rose; Henri R Ford; Ali Salim; Steven C Stain; Shahid Shafi; Beth Sutton; David Hoyt; Yvonne T Maddox; L D Britt Journal: JAMA Surg Date: 2016-06-01 Impact factor: 14.766
Authors: Claudia Allemani; Hannah K Weir; Helena Carreira; Rhea Harewood; Devon Spika; Xiao-Si Wang; Finian Bannon; Jane V Ahn; Christopher J Johnson; Audrey Bonaventure; Rafael Marcos-Gragera; Charles Stiller; Gulnar Azevedo e Silva; Wan-Qing Chen; Olufemi J Ogunbiyi; Bernard Rachet; Matthew J Soeberg; Hui You; Tomohiro Matsuda; Magdalena Bielska-Lasota; Hans Storm; Thomas C Tucker; Michel P Coleman Journal: Lancet Date: 2014-11-26 Impact factor: 79.321
Authors: Jelena Mustra Rakic; Chun Liu; Sudipta Veeramachaneni; Dayong Wu; Ligi Paul; C-Y Oliver Chen; Lynne M Ausman; Xiang-Dong Wang Journal: Cancer Prev Res (Phila) Date: 2019-06-08
Authors: Claudia Allemani; Rhea Harewood; Christopher J Johnson; Helena Carreira; Devon Spika; Audrey Bonaventure; Kevin Ward; Hannah K Weir; Michel P Coleman Journal: Cancer Date: 2017-12-15 Impact factor: 6.860
Authors: Bin Liu; Julio Ricarte Filho; Apurva Mallisetty; Cassandra Villani; Anastasia Kottorou; Kristen Rodgers; Chen Chen; Tomoaki Ito; Kyla Holmes; Nicole Gastala; Klara Valyi-Nagy; Odile David; Ron C Gaba; Christian Ascoli; Mary Pasquinelli; Lawrence E Feldman; Malek G Massad; Tza-Huei Wang; Ignacio Jusue-Torres; Enrico Benedetti; Robert A Winn; Malcolm V Brock; James G Herman; Alicia Hulbert Journal: Clin Cancer Res Date: 2020-05-19 Impact factor: 12.531
Authors: Carolyn J Presley; Daiwei Tang; Pamela R Soulos; Anne C Chiang; Janina A Longtine; Kerin B Adelson; Roy S Herbst; Weiwei Zhu; Nathan C Nussbaum; Rachael A Sorg; Vineeta Agarwala; Amy P Abernethy; Cary P Gross Journal: JAMA Date: 2018-08-07 Impact factor: 56.272